These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38455854)

  • 21. Management of carcinoid syndrome: a systematic review and meta-analysis.
    Hofland J; Herrera-Martínez AD; Zandee WT; de Herder WW
    Endocr Relat Cancer; 2019 Mar; 26(3):R145-R156. PubMed ID: 30608900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carcinoid syndrome: diagnosis and medical management.
    van der Lely AJ; de Herder WW
    Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):850-60. PubMed ID: 16444370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.
    Ambrosini V; Kunikowska J; Baudin E; Bodei L; Bouvier C; Capdevila J; Cremonesi M; de Herder WW; Dromain C; Falconi M; Fani M; Fanti S; Hicks RJ; Kabasakal L; Kaltsas G; Lewington V; Minozzi S; Cinquini M; Öberg K; Oyen WJG; O'Toole D; Pavel M; Ruszniewski P; Scarpa A; Strosberg J; Sundin A; Taïeb D; Virgolini I; Wild D; Herrmann K; Yao J
    Eur J Cancer; 2021 Mar; 146():56-73. PubMed ID: 33588146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Misleading clinical presentation of carcinoid syndrome.
    Famerée L; Van Lier C; Borbath I; Yildiz H; Lemaire J; Baeck M
    Acta Gastroenterol Belg; 2021; 84(3):501-503. PubMed ID: 34599576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies.
    Vitale G; Carra S; Alessi Y; Campolo F; Pandozzi C; Zanata I; Colao A; Faggiano A; On Behalf Of The Nike Group
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of
    Lodge MA; Solnes LB; Chaudhry MA; Wahl RL
    Mol Imaging Biol; 2021 Oct; 23(5):766-774. PubMed ID: 33829361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
    Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
    Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic surgery for metastases from neuroendocrine tumors.
    Sarmiento JM; Que FG
    Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors.
    Eriksson B; Bergström M; Lilja A; Ahlström H; Långström B; Oberg K
    Acta Oncol; 1993; 32(2):189-96. PubMed ID: 7686763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of [
    Deleu AL; Laenen A; Decaluwé H; Weynand B; Dooms C; De Wever W; Jentjens S; Goffin K; Vansteenkiste J; Van Laere K; De Leyn P; Nackaerts K; Deroose CM
    EJNMMI Res; 2022 May; 12(1):28. PubMed ID: 35524900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
    Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
    Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
    Pasricha G; Padhi P; Daboul N; Monga DK
    Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms.
    Boutzios G; Kaltsas G
    Front Horm Res; 2015; 44():40-57. PubMed ID: 26303703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids.
    Jindal T; Kumar A; Venkitaraman B; Dutta R; Kumar R
    Korean J Intern Med; 2010 Dec; 25(4):386-91. PubMed ID: 21179276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
    Anthony LB; Kulke MH; Caplin ME; Bergsland E; Öberg K; Pavel M; Hörsch D; Warner RRP; O'Dorisio TM; Dillon JS; Lapuerta P; Kassler-Taub K; Jiang W
    Oncologist; 2019 Aug; 24(8):e662-e670. PubMed ID: 30651397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogeneity of SSTR2 Expression Assessed by
    Fonti R; Panico M; Pellegrino S; Pulcrano A; Vastarella LA; Torbati AHM; Giuliano M; Palmieri G; De Placido S; Del Vecchio S
    J Nucl Med; 2022 Oct; 63(10):1509-1514. PubMed ID: 35273092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential for Increasing Uptake of Radiolabeled
    Pollard JH; Menda Y; Zamba KD; Madsen M; O'Dorisio MS; O'Dorisio T; Bushnell D
    Cancer Biother Radiopharm; 2021 Oct; 36(8):632-641. PubMed ID: 34252288
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
    Kumar R; Sharma P; Garg P; Karunanithi S; Naswa N; Sharma R; Thulkar S; Lata S; Malhotra A
    Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
    Graf J; Pape UF; Jann H; Denecke T; Arsenic R; Brenner W; Pavel M; Prasad V
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):881-894. PubMed ID: 31414209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.